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Following the development of highly effective direct acting antiviral (DAA) compounds for the 
treatment of the hepatitis C virus (HCV), the World Health Organisation (WHO) has set out plans for 
eradication by 2030. Many barriers must be surmounted before this can be achieved, including buy-
in from governments and policy-makers, reduced drug costs and improved infrastructure for the 
pathway from diagnosis to treatment. A comprehensive set of guidelines were produced by WHO in 
2014, updated in 2016 and are due to be revised later this year.1 It is likely that they will be 
substantially improved following the addition of pan-genotypic regimens; this is of particular 
importance in low and middle income countries (LMICs) where the cost of genotyping may be 
prohibitively high. In such areas, information on HCV prevalence and serotype is extremely limited.2 
Very little data on circulating genetic strains and polymorphisms that may be associated with 
resistance to DAAs are available. One of the most variable of the RNA viruses, HCV has 7 distinct 
genotypes differing from each other by up to 30% with 86 subtypes varying by 10-25% at the 
nucleotide level. Direct-acting antiviral drugs have improved sustained virological response rates 
significantly to over 95% in trials in high income countries (HICs), but variants associated with drug 
resistance have emerged both in vitro and in clinical trials, leading guidance to recommend 
resistance testing in treatment failure and in selected regimens at baseline.4 Variation in HCV 
sequences could affect both diagnostic assays and treatment outcomes.  
In this study, we used HCV-GLUE, a new linked dataset and suite of analysis tools for HCV sequence 
data. We identified > 30,000 sequences from NCBI which encode the NS3, NS5A and NS5B viral 
proteins (the targets of DAAs), and mapped these by geographical regions.5 This revealed huge gaps 
in sequence data in the majority of LMICs and some HICs (Figure 1). For example, only 15 sequences 
spanning NS5B are available for the whole sub-Saharan Africa region (Figure 1F).  More work to 
investigate circulating genotypes is needed to inform local governments and policymakers who are 
developing the infrastructure for the diagnosis and treatment of HCV in these regions in order to 
facilitate eradication of the disease. Resistance associated variants (RAVs) could present a barrier to 
the WHO plan for eradication of HCV by 2030 and vigilance is required to monitor transmitted viral 
strains as treatment roll-out occurs. 
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Figure 1. Global distribution of HCV sequence data based on the genes of DAA treatment targets. (A) 
NS3 protease sequences by country (B) Abundance of NS3 sequences by UN sub-regions. (C) NS5A 
sequences by country. (D)Abundance of NS5A sequences by UN sub-regions. (E) NS5B sequences by 
country. (F) Abundance of NS5B sequences by UN sub-regions. 
 
